Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa

Journal of Medicinal Chemistry

Volumn 45, Issue 13, 2002, Pages 2749-2769

  Matter, Hans ^a   Brachvogel, Volker ^a   Lönze, Petra ^a   Walser, Armin ^a   Al Obeidi, Fahad ^a   Wildgoose, Peter ^a   Defossa, Elisabeth ^a   Heinelt, Uwe ^a   Blohm, Peter Michael ^a   Schneider, Detlev ^a   Müller, Andrea ^a   Herok, Silke ^a   Schreuder, Herman ^a   Liesum, Alexander ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMIDINOBENZYL 1H INDOLE 2 CARBOXAMIDE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CORRELATION COEFFICIENT; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HYDROPHOBICITY; PROTEIN PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOCHEMISTRY; VALIDATION PROCESS;

AMIDES; AMIDINES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; FACTOR XA; INDOLES; MODELS, MOLECULAR; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SERINE PROTEINASE INHIBITORS; STEREOISOMERISM;

EID: 0037142372     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0111346     Document Type: Article

References (97)

1. Direct factor Xa inhibitors
2. The coagulation cascade: Initiation, maintenance, and regulation
3. Surface dependent reactions of the vitamin K-dependent enzyme complexes
4. Compounds and assembly of the factor Xa activating complex
5. Antithrombotic strategies targeting thrombn activities, thrombin receptors and thrombin generation
6. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa
7. DX-9065a, an orally active, specific inhibitor of factor Xa inhibits thrombosis without affecting bleeding time in rats
8. Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial
9. Potential advantages of direct acting thrombin inhibitors
10. Factor Xa inhibitors
11. Progress in the design of inhibitors of coagulation factor Xa
12. Factor Xa inhibitors: Recent advances in anticoagulant agents
13. Thrombin and factor Xa inhibitors
14. Perspectives on factor Xa inhibition
15. Discovery of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2′ (methylsulfonyl)-[1,1′-biphenyl]-4-yl]-3- (trifluoromethyl)-1h-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa
16. Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors
17. Synthesis, characterization and structure-activity relationships of amidine-substituted (bis)benzylidene-cycloketone olefine isomers as potent and selective factor Xa inhibitors
18. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1
19. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2
20. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa
21. Sulfonamidopyrrolidinone factor Xa inhibitors: Potency and selectivity enhancements via P-1 and P-4 optimization
22. Tetrahydro-isoquinoline-based factor Xa inhibitors
23. Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: Implications for the inhibition of factor Xa, tPA, and urokinase
24. Design, synthesis and structure-activity relationship of a series of arginine aldehyde factor Xa inhibitors. Part 1: Structures based on the (D)-Arg-Gly-Arg tripeptide sequence
25. Amido-(Propyl and Allyl)-hydroxybenzamidines: Development of achiral inhibitors of factor Xa
26. Nonbenzamidine compounds as selective factor Xa inhibitors
27. Rational Design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors
28. Non-amidine-containing 1,2-dibenzamidobenzene inhibitors of human factor Xa with potent anticoagulant and antithrombotic activity
29. 1,2-Dibenzamidobenzene inhibitors of human factor Xa
30. Structure-based design of potent, amidine-derived inhibitors of factor Xa: Evaluation of selectivity, anticoagulant activity, and antithrombotic activity
31. N2-aroylanthranilamide inhibitors of human factor Xa
32. Discovery of a novel, potent, and specific family of factor Xa inhibitors via combinatorial chemistry
33. Structures of thrombin retro-inhibited with SEL2711 and SEL2770 as they relate to factor Xa binding
34. Structure of human Des(1-45) factor Xa at 2.2 Å resolution
35. Crystal structures of human factor Xa complexed with potent inhibitors
36. Structural basis for chemical inhibition of human blood coagulation factor Xa
37. X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition
38. Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors
39. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa
40. Unexpected Binding mode of tick anticoagulant peptide complexed to bovine factor Xa
41. Cation-π interactions in chemistry and biology: A new view of benzene, Phe, Tyr, and Trp
42. Solid-phase optimisation of achiral amidinobenzyl indols as potent and selective factor Xa inhibitors
43. 3D-quantitative structure-activity relationships of human immunodeficiency virus type-1 protein as inhibitors: Comparative molecular field analysis of 2-heterosubstituted statine derivatives. Implication for the design of novel inhibitors
44. The protein data bank: A computer-based archival file for macromolecular structures
45. The Protein Data Bank
46. Comparative Molecular Field Analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins
47. Comparative Molecular Field Analysis (CoMFA). 2. Towards its use with 3D-structural databases
48. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity
49. Multivariate structure-activity relationship between data from a battery of biological tests and an ensemble of structure descriptors: The PLS method
50. Notes on the history and nature of Partial Least Squares (PLS) modelling
51. Cross-validatory estimation of the number of components in factor and principal component models
52. Computer intensive methods for statistics
53. Crossvalidation, bootstrapping and partial least squares compared with multiple regression in conventional QSAR studies
54. Conversion of "obstinate" nitriles to amidines by Garigipati's reaction
55. A convenient synthesis of 5-substituted-7-β-D-arabinofuranosylpyrrolo[2,3-d]pyrimidines structurally related to the antibiotics toyocamycin and sangivamycin
56. Synthesis of Nα-(arylsulfonylglycyl)amidinophenylalaninamides as highly active inhibitors of thrombin
57. Evaluation of single-crystal x-ray diffraction data from a position sensitive detector
58. Maximally diagonal force constants in dependent angle-bending coordinates. 2. Implications for the design of empirical force fields
59. Halgren MMFF94s option for energy minimization studies
60. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules
61. QXP: Powerful, rapid computer algorithms for structure-based drug design
62. A fast flexible docking method using an incremental construction algorithm
63. An alternative method for the alignment of molecular structures: Maximizing electrostatic and steric overlap
64. Recommendations for CoMFA studies and 3D QSAR publications
65. CoMFA: Scope and limitations
66. The developing practice of comparative molecular field analysis
67. Extending the trend vector: The trend matrix and sample-based partial least squares
68. The probability of chance correlation using partial least squares (PLS)
69. PLS validation by progressive scrambling
70. Comparison of some measures for the determination of intermolecular structural similarity
71. Implementing drug screening programs using molecular similarity methods
72. Simulation analysis of experimental design strategies for screening random compounds as potential new drugs and agrochemicals
73. Random or rational design? Evaluation of diverse compound subsets from chemical structure databases
74. Structural requirements for inhibition of the neuronal nitric oxide synthase (NOS-I): 3D-QSAR analysis of 4-oxo- and 4-aminopteridine based inhibitors
75. Comparative molecular similarity index analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries
76. Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa
77. Comparative molecular similarity indices analysis. CoMSIA
78. A computational study of cation-π interactions vs salt bridges in aqueous media: Implications for protein engineering
79. Cation-π interactions in structural biology
80. The cation-π interaction
81. Identification of a binding site for quertary amines in factor Xa
82. Planar stacking interactions of arginine and aromatic side-chains in proteins
83. Cation-π versus OH-π interactions in proteins: A density functional study
84. GRID/CPCA: A new computational tool to design selective ligands
85. Combining structure-based design and 3D-QSAR towards the discovery of non-chiral, potent and selective factor Xa inhibitors
86. Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and x-ray structure analysis